# PT-141 (Bremelanotide): What the Approved-Population Research Shows > PT-141 (bremelanotide) is a melanocortin MC4R agonist approved for one use: HSDD in premenopausal women. A cited reading of the mechanism, the trials, and the honest tolerability cost. Approved for exactly one thing — low sexual desire in premenopausal women — and nothing else. The cited evidence sits on one side; the field reports are pinned to the other, where they belong. ## The short version Most of what you will read about **PT-141** online is breathless. Here is the un-breathless version. PT-141 (the research name for bremelanotide) is a small lab-made peptide that flips a switch in the brain rather than in the bloodstream. The U.S. FDA approved it in June 2019 for one use only: HSDD (hypoactive sexual desire disorder — persistent low sexual desire that causes real personal distress) in premenopausal women [6]. In the trials it worked, but the effect was modest, and roughly four in ten people on it long-term felt nauseated [4]. Every other use — men, erectile problems, postmenopausal women — is off-label and far less studied. That is the whole gallery, in one paragraph. ## What is PT-141? PT-141 is bremelanotide: a synthetic cyclic heptapeptide (a ring of seven amino acids, joined head-to-tail and braced with a chemical bridge) modelled on the natural hormone alpha-MSH (alpha-melanocyte-stimulating hormone — a brain-and-skin signalling peptide your body already makes) [1]. It activates **melanocortin MC4R/MC3R receptors** (brain switches that influence sexual desire, appetite, and skin pigment), chiefly the MC4R subtype, in the hypothalamus and limbic system [1]. The shorthand is simple: where a PDE-5 inhibitor (the erectile-blood-flow drug class — sildenafil, tadalafil) works on plumbing, PT-141 works on wiring. It does not touch vascular smooth muscle; it nudges the central circuitry of sexual motivation [5]. That single distinction — [how the melanocortin mechanism works](/) — explains nearly everything else about it: what it is approved for, what it is not, and why the side-effect list looks the way it does. The finished, regulated form is **bremelanotide injection**; material sold as 'PT-141 research chemical' is the same molecule prepared for laboratory use only, outside that approval [6]. If you only read one page after this, make it [doses used in the research](/dosage), where the single approved figure is set apart from the research-only numbers. ## PT-141 as a melanocortin-agonist peptide Asked the long-tail way — what is the **PT-141 peptide**? — the answer is a melanocortin-agonist peptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, molecular weight 1025.2 Da, CAS 189691-06-3 [1]. The cyclic lactam ring is the point of the design: closing the peptide into a loop makes it more stable than the linear melanocortin peptides it descends from. Mechanistically it is an agonist (a key that turns the lock on) at MC3R and MC4R, the two melanocortin receptor subtypes concentrated in the central nervous system. Systemic dosing produced erections in rats and nonhuman primates and lit up hypothalamic neurons in the earliest pharmacology, and a dose-dependent erectile response in men with erectile dysfunction in the same 2003 program [1]. In female rats it selectively increased solicitational (desire-driven) sexual behaviour without changing reflexive behaviour or general activity — the first agent reported to act on appetitive female sexual behaviour specifically [2]. Those two animal threads — central activation, desire-selective behaviour — are the spine of everything the human trials later measured. ## What the approved-population trials measured Two identical Phase 3 randomised controlled trials — the RECONNECT studies, 1,267 premenopausal women with HSDD between them — tested bremelanotide 1.75 mg given under the skin as needed against placebo over 24 weeks [3]. Both hit their two co-primary endpoints. Pooled, sexual desire (the FSFI desire score) rose +0.35 and the distress tied to low desire (FSDS-DAO item 13) fell -0.33 versus placebo, both at P<.001 [3]. A 52-week open-label extension in 684 women sustained the desire improvement with no new safety signals [4]. Real, but read the size, not just the asterisk. Independent re-analyses argued those effects are small and questioned whether they are clinically meaningful [8]. We hang both placards side by side: [published research findings](/research) on one wall, and the critics who qualified them on the same wall. That is the honest register this site keeps. The mechanism backs up the modest-but-real reading. A 2022 fMRI study in 31 premenopausal women with HSDD found that activating MC4R raised sexual desire for up to 24 hours — far longer than the drug stayed in the blood — and changed how the brain processed erotic images [5]. That is the clearest signal that PT-141 is doing something central and specific, not a placebo shimmer. The effect is small in the questionnaire scores and unmistakable in the brain imaging at the same time; holding both of those facts at once is the whole point of reading the literature instead of the marketing. ## Approved for one thing. Off-label for everything else. This is the line that gets blurred everywhere else, so we draw it in yellow. Bremelanotide is FDA-approved (NDA 210557, June 21, 2019) for acquired, generalized HSDD in **premenopausal women only** [6]. It is not approved for men, not for postmenopausal women, not for erectile dysfunction, and not to 'enhance' anything [6]. The male and erectile evidence is early-phase and investigational — a 2003 dose-response signal in men with ED [1] and a 2024 sexual-medicine clinic abstract describing real-world off-label male use [12]. Interesting, not established. And there is a tolerability cost worth seeing before anything else: nausea is common, blood pressure rises transiently (so the label warns against use in uncontrolled hypertension or known cardiovascular disease), and repeated frequent dosing can darken skin and gums [4][6]. Read [the HSDD indication in women](/female-hsdd), read [side effects and tolerability](/side-effects), and read the [common questions](/faq) before you read the hype. That is the gallery in brief. The rest of this site walks each wall in detail: the trials and mechanism, the doses, the tolerability cost in full, and the exact approval scope. Every quantitative claim resolves to a numbered entry in the [study references](/references) — the field reports, pinned in hot pink elsewhere, deliberately do not. --- A curatorial wall of the PT-141 (bremelanotide) record — the one approved indication and the nausea-led tolerability cost hung in front, the modest effect shown beside the numbers that qualify it, and the field reports pinned to the far side as unverified; the 'Order' here is how the studies are arranged, never a checkout, and nothing is dosed, dispensed, or sold.